ANN ARBOR, Mich., March 3, 2011 /PRNewswire/ -- Adeona
Pharmaceuticals, Inc. (Amex: AEN), a developer of innovative
medicines for serious central nervous system diseases, announced
today the appointment of George J.
Brewer, M.D., as Senior Vice President of Research &
Development. Dr. Brewer joins the Adeona management team
after serving as the Chairman of the Company's Scientific Advisory
Board for seven years.
Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus
Professor of Human Genetics and Internal Medicine at the
University of Michigan. He was a
member of the National Science Council's "Committee on Copper in
Drinking Water" convened at the request of the Environmental
Protection Agency in 2000 to consider the issue of what level of
copper in drinking water could be considered "safe." Dr. Brewer has
published over 500 scientific papers, several books and is the
inventor of oral zinc therapy approved by the Food & Drug
Administration (FDA) in 1997, now standard of care for chronic
Wilson's disease.
"We are pleased that Dr. Brewer, a respected medical innovator
and developer of zinc-based therapies over his career, accepted our
offer to join Adeona's management team. As the Chairman of our
Scientific Advisory Board, Dr. Brewer provided significant guidance
with regard to our clinical development programs, and we look
forward to his continued valuable contributions in his new role as
Senior Vice President of Research & Development," stated
James S. Kuo, M.D., M.B.A., Adeona's
Chairman and CEO. "We also appreciate the condolences received
following the passing of our colleague and friend, David Newsome. While this was an unexpected loss
for the Company, we believe the appointment of Dr. Brewer positions
our clinical development programs for continued advancement."
The study coordinators at the three clinical sites conducting
Adeona's study evaluating reaZin™ (zinc cysteine) for the
dietary management of Alzheimer's disease and mild cognitive
impairment continue the follow-up appointments with the patients
enrolled in this study. Adeona has also contracted a replacement
clinical trial associate to monitor the study on behalf of the
Company. Patients are scheduled to complete their final study
visits by the end of March 2011. As
previously announced, Adeona plans to present the results of its
pivotal clinical trial in a poster presentation at the American
Academy of Neurology Annual Meeting on April
14, 2011 at the Hawaii
Convention Center in Honolulu,
Hawaii. A concurrent press release will also be
distributed.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company developing innovative
medicines for the treatment of serious central nervous system
diseases. The Company's strategy is to license product candidates
that have demonstrated a certain level of clinical efficacy and
develop them to a stage that results in a significant commercial
collaboration. Currently, Adeona is developing the following
product candidates: a prescription medical food for Alzheimer's
disease, and drugs for multiple sclerosis, fibromyalgia,
age-related macular degeneration and rheumatoid arthritis. For more
information, please visit Adeona's website at
www.adeonapharma.com.
This release includes forward-looking statements on Adeona's
current expectations and projections about future events. In some
cases forward-looking statements can be identified by terminology
such as "may," "should," "potential," "positions," "continue,"
"expects," "anticipates," "intends," "plans," "believe,"
"estimates," and similar expressions. These statements are based
upon current beliefs, expectations and assumptions and are subject
to a number of risks and uncertainties, many of which are difficult
to predict and include statements regarding the timing and results
of our clinical studies and our ability to successfully develop
products with superior benefits. The forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from those reflected in
Adeona's forward-looking statements include, among others,
the availability of financial and other resources and the
allocation of resources among different potential uses, a
failure of our clinical trials to be completed on time or to
achieve desired results, a failure of the new branding to achieve
desired results, a failure of our clinical reference laboratory to
continue to grow and achieve revenue or a failure by us or our
strategic partners to successfully commercialize products and other
factors described in Adeona's report on Form 10-K for the year
ended December 31, 2009
and any other filings with the SEC. The information in this
release is provided only as of the date of this release, and Adeona
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
SOURCE Adeona Pharmaceuticals, Inc.